Perioperativer Umgang mit Antikoagulanzien und Plättchenhemmern bei allgemeinchirurgischen Eingriffen

Philipp Lauten; Carsten Salomon; Harald Lapp

doi:10.1055/s-0043-109364

Allgemein- und Viszeralchirurgie up2date, Table of Contents

Allgemein- und Viszeralchirurgie up2date 2017; 11(05): 529-547
DOI: 10.1055/s-0043-109364

Perioperative Medizin

Georg Thieme Verlag KG Stuttgart · New York

Perioperativer Umgang mit Antikoagulanzien und Plättchenhemmern bei allgemeinchirurgischen Eingriffen

Philipp Lauten

,

Carsten Salomon

,

Harald Lapp

Abstract

All articles of this category

Die Entscheidung, ob ein Bridging erforderlich ist, wie es durchgeführt wird oder ob darauf verzichtet werden kann, ist komplex. Evidenzbasierte Leitlinien sind derzeit nicht verfügbar. Dieser Artikel stellt das verfügbare Wissen vor und soll und Entscheidungshilfen liefern, die in institutionsspezifische Handlungsempfehlungen übertragen werden können.

Schlüsselwörter

orale Antikoagulation - Thrombozytenhemmung - Antiaggregation - perioperatives Vorgehen - Risikostratifizierung - Blutungsrisiko - thromboembolische Komplikationen

Full Text

References

Literatur
1 Hein L, Wille H. Antithrombotika und Antihämorrhagika. In: Schwabe U, Paffrath D. Hrsg. Arzneiverordnungs-Report. Berlin, Heidelberg: Springer; 2016: 351-368 doi:10.1007/978-3-662-50351-5_18
2 Daels FP, Gaizauskas A, Rioja J. et al. Age-related prevalence of diabetes mellitus, cardiovascular disease and anticoagulation therapy use in a urolithiasis population and their effect on outcomes: the Clinical Research Office of the Endourological Society Ureteroscopy Global Study. World J Urol 2015; 33: 859-864 doi:10.1007/s00345-014-1382-6
3 Greenspon AJ, Hart RG, Dawson D. et al. Predictors of stroke in patients paced for sick sinus syndrome. J Am Coll Cardiol 2004; 43: 1617-1622 doi:10.1016/j.jacc.2003.09.067
4 Bardy GH, Lee KL, Mark DB. et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-237 doi:10.1056/NEJMoa043399
5 Coleman J, Baldawi M, Heidt D. The effect anticoagulation status on geriatric fall trauma patients. Am J Surg 2016; 212: 1237-1242 doi:10.1016/j.amjsurg.2016.09.036
6 Leijtens B, Kremers van de Hei K, Jansen J. et al. High complication rate after total knee and hip replacement due to perioperative bridging of anticoagulant therapy based on the 2012 ACCP guideline. Arch Orthop Trauma Surg 2014; 134: 1335-1341 doi:10.1007/s00402-014-2034-4
7 Birnie DH, Healey JS, Wells GA. et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-2093 doi:10.1056/NEJMoa1302946
8 Essebag V, Healey JS, Ayala-Paredes F. et al. Strategy of continued vs. interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial. Am Heart J 2016; 173: 102-107 doi:10.1016/j.ahj.2015.12.007
9 Sanders DL, Shahid MK, Ahlijah B. et al. Inguinal hernia repair in the anticoagulated patient: a retrospective analysis. Hernia 2008; 12: 589-592 doi:10.1007/s10029-008-0405-x discussion 667–668
10 Noda T, Hatano H, Dono K. et al. Safety of early laparoscopic cholecystectomy for patients with acute cholecystitis undergoing antiplatelet or anticoagulation therapy: a single-institution experience. Hepatogastroenterology 2014; 61: 1501-1506
11 Douketis JD, Spyropoulos AC, Kaatz S. et al. Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med 2015; 373: 823-833 doi:10.1056/NEJMoa1501035
12 Douketis JD, Spyropoulos AC, Spencer FA. et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e326S-350S doi:10.1378/chest.11-2298
13 Steinberg BA, Peterson ED, Kim S. et al. Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131: 488-494 doi:10.1161/CIRCULATIONAHA.114.011777
14 Eikelboom JW, Hirsh J, Spencer FA. et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e89S-e119S
15 Wiviott SD, Braunwald E, McCabe CH. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015 doi:10.1056/NEJMoa0706482 NEJMoa0706482 [pii]
16 Ferri N, Corsini A, Bellosta S. Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs 2013; 73: 1681-1709 doi:10.1007/s40265-013-0126-z
17 Harbrecht U. Old and new anticoagulants. Hamostaseologie 2011; 31: 21-27 doi:10.5482/ha-1149
18 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 doi:10.1056/NEJMoa0905561
19 Pollack CV jr, Reilly PA, Eikelboom J et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373: 511-520 doi:10.1056/NEJMoa1502000
20 Investigators E, Bauersachs R, Berkowitz SD. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510 doi:10.1056/NEJMoa1007903
21 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 doi:10.1056/NEJMoa1009638
22 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992 doi:10.1056/NEJMoa1107039
23 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104 doi:10.1056/NEJMoa1310907
24 Stacy ZA, Call WB, Hartmann AP. et al. Edoxaban: A comprehensive review of the pharmacology and clinical data for the management of atrial fibrillation and venous thromboembolism. Cardiol Ther 2016; 5: 1-18 doi:10.1007/s40119-016-0058-2
25 Ha AC, Verma A, Verma S. Oral anticoagulation for stroke prevention amongst atrial fibrillation patients with valvular heart disease: an update. Curr Opin Cardiol 2017; 32: 174-180 doi:10.1097/HCO.0000000000000365
26 Lee LH. DOACs – advances and limitations in real world. Thromb J 2016; 14: 17 doi:10.1186/s12959-016-0111-3
27 Samuelson BT, Cuker A. Measurement and reversal of the direct oral anticoagulants. Blood Rev 2017; 31: 77-84 doi:10.1016/j.blre.2016.08.006
28 Connolly SJ, Milling jr TJ, Eikelboom JW. et al. Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med 2016; 375: 1131-1141 doi:10.1056/NEJMoa1607887
29 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722 doi:10.1016/S0140-6736(13)61720-1
30 Bradbury A, Adam D, Garrioch M. et al. Changes in platelet count, coagulation and fibrinogen associated with elective repair of asymptomatic abdominal aortic aneurysm and aortic reconstruction for occlusive disease. Eur J Vasc Endovasc Surg 1997; 13: 375-380
31 Wendl-Soeldner MA, Moll CW, Kammerlander C. et al. Algorithm for anticoagulation management in geriatric hip fracture patients-Surgeons save Blood. Z Gerontol Geriatr 2014; 47: 95-104 doi:10.1007/s00391-013-0595-4
32 Bonhomme F, Boehlen F, Clergue F. et al. Preoperative hemostatic assessment: a new and simple bleeding questionnaire. Can J Anaesth 2016; 63: 1007-1015 doi:10.1007/s12630-016-0688-9
33 Chee YL, Crawford JC, Watson HG. et al. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140: 496-504 doi:10.1111/j.1365-2141.2007.06968.x
34 White RH. ACP Journal Club. Scores poorly predict major bleeding (c-statistics </= 0.61) during oral anticoagulant therapy. Ann Intern Med 2013; 158: JC13 doi:10.7326/0003-4819-158-6-201303190-02013
35 Smilowitz NR, Oberweis BS, Nukala S. et al. Association between anemia, bleeding, and transfusion with long-term mortality following noncardiac surgery. Am J Med 2016; 129: 315-323 e312 doi:10.1016/j.amjmed.2015.10.012
36 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2016; 134: e123-e155 doi:10.1161/CIR.0000000000000404
37 Frontera JA, Lewin 3rd JJ, Rabinstein AA. et al. Guideline for reversal of antithrombotics in intracranial hemorrhage: a statement for healthcare professionals from the Neurocritical Care Society and Society of Critical Care Medicine. Neurocrit Care 2016; 24: 6-46 doi:10.1007/s12028-015-0222-x
38 Siegal DM, Curnutte JT, Connolly SJ. et al. Andexanet Alfa for the reversal of factor Xa inhibitor activity. N Engl J Med 2015; 373: 2413-2424 doi:10.1056/NEJMoa1510991
39 Simpson PM, Brew CJ, Whitehouse SL. et al. Complications of perioperative warfarin therapy in total knee arthroplasty. J Arthroplasty 2014; 29: 320-324 doi:10.1016/j.arth.2012.11.003
40 Azoulay L, DellʼAniello S, Simon TA. et al. Initiation of warfarin in patients with atrial fibrillation: early effects on ischaemic strokes. Eur Heart J 2014; 35: 1881-1887 doi:10.1093/eurheartj/eht499
41 Rhodes DA, Severson EP, Hodrick JT. et al. Discontinuation of warfarin is unnecessary in total knee arthroplasty. Clin Orthop Relat Res 2010; 468: 120-126 doi:10.1007/s11999-009-1128-8
42 Brotman DJ, Streiff MB. Overuse of bridging anticoagulation for patients with venous thromboembolism: first, do no harm. JAMA Intern Med 2015; 175: 1169-1170 doi:10.1001/jamainternmed.2015.1858
43 Shaikh AY, McManus DD. A bridge too far? Findings of bridging anticoagulation use and outcomes in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Circulation 2015; 131: 448-450 doi:10.1161/CIRCULATIONAHA.114.014319
44 Flaker GC, Theriot P, Binder LG. et al. Management of periprocedural anticoagulation: a survey of contemporary practice. J Am Coll Cardiol 2016; 68: 217-226 doi:10.1016/j.jacc.2016.04.042